1.
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
by Rothwell, Peter M, Prof
The Lancet (British edition), 2010, Vol.375 (9718), p.895-905
2.
Epidemiology of stroke and high blood pressure in Africa
by Mensah, G A
Heart (British Cardiac Society), 2008-06, Vol.94 (6), p.697-705
3.
Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study
by O'Donnell, Martin J, Dr
The Lancet (British edition), 2016, Vol.388 (10046), p.761-775
4.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
by Ruff, Christian T, Dr
The Lancet (British edition), 2014, Vol.383 (9921), p.955-962
5.
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report
by Lip, Gregory Y H
Chest, 2018-11, Vol.154 (5), p.1121-1201
6.
Interpretation of the evidence for the efficacy and safety of statin therapy
by Collins, Rory, Prof
The Lancet (British edition), 2016, Vol.388 (10059), p.2532-2561
7.
Recent advances in the epidemiology, outcome, and prevention of myocardial infarction and stroke in sub-Saharan Africa
by Ntsekhe, Mpiko
Heart (British Cardiac Society), 2013-09, Vol.99 (17), p.1230-48
8.
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
by Ridker, Paul M, MD
The American heart journal, 2011, Vol.162 (4), p.597-605
9.
Stroke prevention in atrial fibrillation
by Freedman, Ben, Prof
The Lancet (British edition), 2016, Vol.388 (10046), p.806-817
10.
Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial
by Bonati, Leo H, MD
The Lancet (British edition), 2015, Vol.385 (9967), p.529-538
11.
Achieved Blood Pressures in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study: Challenges and Lessons Learned
by Pergola, Pablo E
American journal of hypertension, 2014-08-01, Vol.27 (8), p.1052-1060
12.
Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials
by Rothwell, Peter M, Prof
The Lancet (British edition), 2016-07-23, Vol.388 (10042), p.365-375
13.
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of...
by Wallentin, Lars, Prof
The Lancet (British edition), 2010, Vol.376 (9745), p.975-983
14.
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
by Fulcher, Jordan
The Lancet (British edition), 2015, Vol.385 (9976), p.1397-1405
15.
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial
by Derdeyn, Colin P, Prof
The Lancet (British edition), 2014, Vol.383 (9914), p.333-341
16.
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
by Holmes, David R, Prof
The Lancet (British edition), 2009, Vol.374 (9689), p.534-542
17.
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
by Windecker, Stephan
The American heart journal, 2017-02, Vol.184, p.81-87
18.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
by Baigent, C
The Lancet (British edition), 2010, Vol.376 (9753), p.1670-1681
19.
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
by Goette, Andreas, Prof
The Lancet (British edition), 2016, Vol.388 (10055), p.1995-2003
20.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised...
by Dormandy, John A
The Lancet (British edition), 2005, Vol.366 (9493), p.1279-1289
